[
  {
    "ts": null,
    "headline": "Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease",
    "summary": "Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.",
    "url": "https://finnhub.io/api/news?id=4402ff68f58c1ddf64c786dac9762e5f7a3dfefb70268840fd380d811f7a8162",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752063840,
      "headline": "Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease",
      "id": 135836435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.",
      "url": "https://finnhub.io/api/news?id=4402ff68f58c1ddf64c786dac9762e5f7a3dfefb70268840fd380d811f7a8162"
    }
  }
]